Efficacy and safety of peficitinib in rheumatoid arthritis

Research output: Contribution to journalArticle

Abstract

Peficitinib is a Janus kinase (JAK) inhibitor, newly developed and approved in Japan. In contrast to other JAK inhibitors, it is a unique pan-JAK inhibitor, demonstrating inhibition of all JAKs. In patients with rheumatoid arthritis with an inadequate response to previous disease-modifying anti-rheumatic drugs, the efficacy of peficitinib (100 mg and 150 mg) has been confirmed with a comparison to placebo in Phase 2b and 3 trials conducted in Asia. Reportedly, peficitinib was well tolerated for 52 weeks during the trial duration, as well as for the next few years in a subsequent, ongoing long-term extension study. Safety signals, especially, the increased risk of herpes zoster was comparable with other JAK inhibitors.

Original languageEnglish
Pages (from-to)773-778
Number of pages6
JournalModern rheumatology
Volume30
Issue number5
DOIs
Publication statusPublished - 2020 Sep 2

Keywords

  • Rheumatoid arthritis
  • janus kinase
  • peficitinib

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Efficacy and safety of peficitinib in rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this